Preview Mode Links will not work in preview mode

Jul 31, 2019

Meet The Professors: Key Questions and Emerging Research in the Management of Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma — Part 1: A special video supplement to a CME symposium held at the 2019 ASCO Annual Meeting featuring Dr Smith’s comments on the application of emerging research to patient care:

  • Appropriate management of molecular subtypes of diffuse large B-cell lymphoma (DLBCL); challenges in improving outcomes with the addition of novel agents to front-line R-CHOP (0:00)
  • Smart Start study: Final results with a rituximab/lenalidomide/ibrutinib lead-in before the combination with chemotherapy for patients with newly diagnosed DLBCL (3:25)
  • Importance of the interval between diagnosis and treatment for newly diagnosed DLBCL and implications for bias in clinical trials (7:05)
  • Risk of relapse with germinal center versus non-germinal center subtypes of DLBCL (8:19)
  • Activity and tolerability of the recently FDA-approved anti-CD79b antibody-drug conjugate polatuzumab vedotin in combination with bendamustine/rituximab (BR) for relapsed/refractory (R/R) DLBCL (9:45)
  • Activity of single-agent polatuzumab vedotin in patients with R/R DLBCL; integration of polatuzumab vedotin/BR into clinical practice (12:06)
  • Therapeutic options and investigational approaches for R/R DLBCL (14:50)
  • POLARIX: An ongoing Phase III trial comparing polatuzumab vedotin with R-CHP to R-CHOP for patients with previously untreated DLBCL (17:22)
  • Variations in chimeric antigen receptor (CAR) T-cell constructs; activity and tolerability of different CAR T-cell therapy products for R/R DLBCL (19:37)
  • Integration of CAR T-cell therapy into the treatment algorithm for R/R DLBCL (24:12)
  • Neurologic toxicity and cytokine release syndrome associated with CAR T-cell therapy (27:01)
  • Selection and sequencing of therapy for patients with R/R mantle cell lymphoma (MCL) (32:00)
  • Drug activity and tolerability and patient quality of life with ibrutinib compared to acalabrutinib (34:42)
  • Results of the Phase III ECOG-E1912 trial evaluating up-front ibrutinib/rituximab versus FCR (fludarabine/cyclophosphamide/rituximab) for younger patients with chronic lymphocytic leukemia (CLL) (38:05)
  • Alliance A041202 trial: Efficacy and tolerability of ibrutinib alone or in combination with either rituximab or BR for older patients with untreated CLL (42:44)
  • Response rates and duration of minimal residual disease (MRD) negativity with limited-duration nonchemotherapy combination regimens for previously untreated CLL (44:28)
  • Risk assessment, prevention and management of venetoclax-associated tumor lysis syndrome (48:39)
  • Activity and tolerability of acalabrutinib alone or in combination with obinutuzumab for CLL (54:44)
  • Second- and third-line therapy options for patients with CLL (56:54)
  • Perspective on the results of the Phase III RELEVANCE trial: Lenalidomide/rituximab (R2) versus rituximab/chemotherapy, each followed by maintenance rituximab, for patients with newly diagnosed follicular lymphoma (FL) (59:00)
  • Available data with and current clinical role of R2 for patients with R/R FL (1:0m49)
  • Comparison of the activity and side-effect profiles of approved and investigational PI3 kinase inhibitors for R/R FL (1:04:02)
  • Approach to choosing among brentuximab vedotin with doxorubicin/vinblastine/dacarbazine (AVD), standard AVD/bleomycin (ABVD) and response-adapted ABVD as first-line therapy for advanced classical Hodgkin lymphoma (1:06:24)
  • Activity of brentuximab vedotin alone or in combination with nivolumab in patients with R/R Hodgkin lymphoma (1:09:48)

CME information and select publications